Roche Holding AG Share Holder Equity 2012-2025 | RHHBY
Roche Holding AG share holder equity from 2012 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
- Roche Holding AG share holder equity for the quarter ending June 30, 2025 was $41.075B, a 22.44% increase year-over-year.
- Roche Holding AG share holder equity for 2024 was $41.075B, a 10.86% increase from 2023.
- Roche Holding AG share holder equity for 2023 was $37.052B, a 10.44% increase from 2022.
- Roche Holding AG share holder equity for 2022 was $33.549B, a 8.18% increase from 2021.
|
Roche Holding AG Annual Share Holder Equity (Millions of US $) |
|
|---|---|
| 2024 | $41,075 |
| 2023 | $37,052 |
| 2022 | $33,549 |
| 2021 | $31,012 |
| 2020 | $42,422 |
| 2019 | $36,100 |
| 2018 | $31,046 |
| 2017 | $29,480 |
| 2016 | $26,806 |
| 2015 | $24,248 |
| 2014 | $23,591 |
| 2013 | $22,930 |
| 2012 | $17,850 |
| 2011 | $16,398 |
|
Roche Holding AG Quarterly Share Holder Equity (Millions of US $) |
|
|---|---|
| 2024-12-31 | $41,075 |
| 2024-06-30 | $36,351 |
| 2023-12-31 | $37,052 |
| 2023-06-30 | $33,755 |
| 2022-12-31 | $33,549 |
| 2022-06-30 | $29,976 |
| 2021-12-31 | $31,012 |
| 2021-06-30 | $44,192 |
| 2020-12-31 | $42,422 |
| 2020-06-30 | $36,128 |
| 2019-12-31 | $36,100 |
| 2019-06-30 | $30,948 |
| 2018-12-31 | $31,046 |
| 2018-06-30 | $30,607 |
| 2017-12-31 | $29,480 |
| 2017-06-30 | $25,671 |
| 2016-12-31 | $26,806 |
| 2016-06-30 | $21,726 |
| 2015-12-31 | $24,248 |
| 2015-06-30 | $20,421 |
| 2014-12-31 | $23,591 |
| 2014-06-30 | $21,923 |
| 2013-12-31 | $22,930 |
| 2013-06-30 | $17,059 |
| 2012-12-31 | $17,850 |
| 2012-06-30 | $12,918 |
| 2011-12-31 | $16,398 |
| 2011-06-30 | $12,462 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $363.891B | $76.450B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $965.086B | 42.17 |
| Johnson & Johnson (JNJ) | United States | $572.906B | 22.02 |
| AbbVie (ABBV) | United States | $387.093B | 21.90 |
| Novartis AG (NVS) | Switzerland | $325.207B | 17.14 |
| Merck (MRK) | United States | $297.222B | 13.35 |
| Novo Nordisk (NVO) | Denmark | $193.513B | 11.08 |
| Pfizer (PFE) | United States | $150.614B | 8.20 |
| Sanofi (SNY) | France | $115.828B | 10.72 |
| Innoviva (INVA) | United States | $1.613B | 8.08 |